Use of an RNA interference screen-derived mitotic and ceramide pathway metagene to predict response to paclitaxel combination chemotherapy in primary breast cancer.
Swanton C, Juul N, Larkin J, Eklund A, Li Q, Desmedt C, Sotiriou C, Pusztai L, Szallasi Z. Use of an RNA interference screen-derived mitotic and ceramide pathway metagene to predict response to paclitaxel combination chemotherapy in primary breast cancer. Journal Of Clinical Oncology 2010, 28: 569-569. DOI: 10.1200/jco.2010.28.15_suppl.569.Peer-Reviewed Original Research